RAPT Therapeutics reported a net loss of $17.58 million for the third quarter of 2025, an improvement compared to a net loss of $18.432 million in the same period last year. The company highlighted significant progress in its clinical trials, including the initiation of a Phase 2b trial for ozureprubart in food allergy and positive topline data from a Phase 2 trial in chronic spontaneous urticaria. A public offering of $250 million was completed to strengthen the balance sheet, extending the cash runway to mid-2028.

RAPT Therapeutics reported a net loss of $17.6 million for the second quarter of 2025, a significant improvement compared to a net loss of $27.7 million in the same period last year. This reduction in loss was primarily driven by a decrease in research and development expenses. The company ended the quarter with $168.9 million in cash and cash equivalents and marketable securities.

RAPT Therapeutics reported a significant decrease in net loss for the first quarter of 2025 compared to the same period in 2024, primarily driven by a reduction in research and development expenses.

RAPT Therapeutics reported a net loss of $18.4 million for the third quarter of 2024, compared to a net loss of $31.4 million for the same period in 2023. Research and development expenses decreased due to lower development costs, while general and administrative expenses also saw a decrease. A workforce reduction was implemented to conserve cash resources.

RAPT Therapeutics reported a net loss of $27.7 million for the second quarter of 2024, compared to a net loss of $25.3 million for the same period in 2023. Research and development expenses increased to $22.6 million, while general and administrative expenses remained relatively unchanged at $6.7 million.

RAPT Therapeutics reported a net loss of $30.5 million for the first quarter of 2024, compared to a net loss of $29.3 million for the first quarter of 2023. The company's cash and cash equivalents and marketable securities totaled $141.6 million as of March 31, 2024. The company also announced the closure of its Phase 2b clinical trial of zelnecirnon in atopic dermatitis and its Phase 2a trial of zelnecirnon in asthma.

RAPT Therapeutics reported a net loss of $30.9 million for the fourth quarter of 2023, compared to a net loss of $23.0 million for the fourth quarter of 2022. The company's cash and cash equivalents and marketable securities totaled $158.9 million as of December 31, 2023.

RAPT Therapeutics reported a net loss of $31.4 million for the third quarter of 2023. Research and development expenses were $27.0 million, and general and administrative expenses were $6.9 million. The company's cash, cash equivalents, and marketable securities totaled $184.8 million as of September 30, 2023, expected to support operations through mid-2025.

RAPT Therapeutics reported a net loss of $25.3 million for the second quarter of 2023, compared to a net loss of $19.2 million for the same period in 2022. The company's research and development expenses increased to $21.6 million, and general and administrative expenses increased to $6.7 million. As of June 30, 2023, the company had cash, cash equivalents and marketable securities of $205 million.

RAPT Therapeutics reported a net loss of $29.3 million for the first quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $231.6 million as of March 31, 2023, expected to support operations through mid-2025.

RAPT Therapeutics reported a net loss of $23.0 million for the fourth quarter of 2022, compared to a net loss of $17.9 million for the fourth quarter of 2021. The company's cash, cash equivalents and marketable securities totaled $249.1 million as of December 31, 2022, providing runway into mid-2025.

RAPT Therapeutics reported a net loss of $21.2 million for the third quarter of 2022, compared to a net loss of $18.7 million for the same period in 2021. The company's research and development expenses for the third quarter of 2022 were $16.6 million, compared to $15.7 million for the same period in 2021. As of September 30, 2022, the Company had cash, cash equivalents and marketable securities of $195.4 million.

RAPT Therapeutics reported a net loss of $19.2 million for the second quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $207.3 million as of June 30, 2022.

RAPT Therapeutics reported a net loss of $20.5 million for the first quarter of 2022, compared to a net loss of $16.5 million for the first quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $173.0 million as of March 31, 2022.

RAPT Therapeutics reported a net loss of $17.9 million for the fourth quarter of 2021, compared to a net loss of $12.7 million for the fourth quarter of 2020. The company's cash, cash equivalents and marketable securities totaled $189.7 million as of December 31, 2021.

RAPT Therapeutics reported a net loss of $18.7 million for the third quarter of 2021, compared to a net loss of $14.6 million for the third quarter of 2020. Research and development expenses were $15.7 million, and general and administrative expenses were $3.8 million.

RAPT Therapeutics reported a net loss of $16.1 million for the second quarter of 2021, compared to a net loss of $12.4 million for the same period in 2020. The company highlighted positive results from a Phase 1b clinical trial and the closing of a public offering that increased their cash reserves.

RAPT Therapeutics reported a net loss of $16.5 million for the first quarter of 2021, compared to a net loss of $13.1 million for the first quarter of 2020. As of March 31, 2021, the Company had cash and cash equivalents and marketable securities of $98.4 million.

RAPT Therapeutics reported a net loss of $12.7 million for the fourth quarter of 2020, compared to $13.2 million for the fourth quarter of 2019. The company's research and development expenses were $10.9 million, and general and administrative expenses were $3.5 million for the same period.

RAPT Therapeutics reported a net loss of $14.6 million for the third quarter of 2020, compared to a net loss of $10.0 million for the third quarter of 2019. Research and development expenses increased to $12.9 million, and general and administrative expenses increased to $3.2 million. The company had cash and cash equivalents and marketable securities of $122.8 million as of September 30, 2020.

RAPT Therapeutics reported a net loss of $12.4 million for the second quarter of 2020, compared to a net loss of $10.6 million for the second quarter of 2019. As of June 30, 2020, the company had cash and cash equivalents and marketable securities of $133.0 million.

RAPT Therapeutics reported a net loss of $13.1 million on revenue of $0.9 million for the first quarter of 2020. The company's cash, cash equivalents and marketable securities totaled $138.2 million as of March 31, 2020.

RAPT Therapeutics reported a net loss of $13.2 million for the fourth quarter of 2019, compared to a net loss of $9.4 million for the fourth quarter of 2018. Research and development expenses for the fourth quarter of 2019 were $10.2 million, compared to $8.4 million for the same period in 2018.